EWTX: Model Update, PT Moves to $51 from $41

Research evidence excerpt

EWTX: Model Update, PT Moves to $51 from $41

July 2, 2026

Debjit Chattopadhyay, Ph.D. debjit.chattopadhyay@guggenheimpartners.com EWTX: Model Update, PT Moves to $51 from $41

212 823 6584

Moritz Reiterer, Ph.D. Key Message: We are updating our model following the planned sale of EWTX's

moritz.reiterer@guggenheimpartners.com muscular dystrophy business unit to Servier (private) for $1.55B upfront and up to $1.1B

212 372 6368 in regulatory / commercial milestones (expected to close in 3Q26), as well as the recent

Ry Forseth, Ph.D. CIRRUS Part D data of EDG-7500 in oHCM and nHCM. -7500 delivered efficacy in

ry.forseth@guggenheimpartners.com line with CMIs or better, combined with a lack of dose-dependent impact on LVEF & no

212 518 9226 instances of LVEF <50% (see our takes HERE and HERE, as well as feedback from our

Hannah Wei KOL HERE). With EDG-7500 poised to be a serious competitor to CMIs in HCM, we are

hannah.wei@guggenheimpartners.com raising our PT to $51 from $41.

212 518 5896

Valuation and Model Update

We increase our PT for EWTX to $51 (prior $41). We are increasing our PoS for EDG-7500

EWTX BUY inmaintainnHCM oHCMto 65%PoS(priorof 55%)65%. basedWe areonalsotheincreasingrecently publishedour marketCIRRUSshare forPartEDG-7500D data; wein

Edgewise Therapeutics, Inc. patients eligible for CMIs to 30% in oHCM (prior 15%) and 50% in nHCM (prior 30%). We are

Sector: Biotechnology removing sevasemten revenue from our model due to the pending sale of EWTX's muscular

dystrophy business to Servier (private) for $1.55B upfront and $1.1B in potential regulatory / Price Target Change commercial milestones. Our PT for EWTX is based on an 11-year discounted cash flow

Share Price $39.15 (DCF) analysis. The model applies a weighted average cost of capital (WACC) of 11.2%